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Actin Dynamics Control SRF Activity
by Regulation of Its Coactivator MAL
by Rho-family small GTPases (Hill et al., 1995). Alter-
ations in actin dynamics are both necessary for the acti-
vation of SRF by extracellular signals and sufficient for
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and Richard Treisman*
Transcription Laboratory its activation in the absence of signal (Sotiropoulos et
al., 1999; Mack et al., 2001). Activation of Rho inducesRoom 401
Cancer Research UK London Research Institute actin polymerization through two effector pathways: the
ROCK-LIM kinase-cofilin pathway stabilizes F actinLincolns Inn Fields Laboratories
44 Lincoln’s Inn Fields (Geneste et al., 2002; Sotiropoulos et al., 1999), while
the mDia1 pathway promotes its assembly (CopelandLondon WC2A 3PX
United Kingdom and Treisman, 2002; Tominaga et al., 2000). Expression
of certain inactive mutant forms of LIMK1, mDia1, and
another cytoskeletal regulator, VASP, can effectively in-
terfere with serum-induced SRF activation (CopelandSummary
and Treisman, 2002; Geneste et al., 2002; Grosse et al.,
2003). Moreover, overexpression of either wild-type orRho GTPases regulate the transcription factor SRF via
their ability to induce actin polymerization. SRF activity nonpolymerizable actin itself also inhibits signaling to
SRF (Posern et al., 2002; Sotiropoulos et al., 1999).responds to G actin, but the mechanism of this has
remained unclear. We show that Rho-actin signaling These data suggest that SRF activity is potentiated by
depletion of either the G actin pool or a G actin tread-regulates the subcellular localization of the myo-
cardin-related SRF coactivator MAL, rearranged in milling intermediate.
The mechanism by which Rho-actin signaling controlst(1;22)(p13;q13) AML. The MAL-SRF interaction dis-
plays the predicted properties of a Rho-regulated SRF SRF activity has remained obscure. Signaling requires
the sequences within the SRF DNA binding domain,cofactor. MAL is predominantly cytoplasmic in serum-
starved cells, but accumulates in the nucleus following which mediate TCF binding (Hill et al., 1993), but the
TCFs themselves do not respond to Rho-actin signalingserum stimulation. Activation of the Rho-actin signal-
ing pathway is necessary and sufficient to promote (Gineitis and Treisman, 2001; Hill et al., 1995). Signaling
also requires sequences at the N terminus of the SRFMAL nuclear accumulation. MAL N-terminal se-
quences, including two RPEL motifs, are required for DNA binding domain and/or the integrity of the SRF
binding site on DNA (Hill et al., 1994). These observationsthe response to signaling, while other regions mediate
its nuclear export (or cytoplasmic retention) and nu- suggest a model in which Rho-actin signaling regulates
a SRF cofactor, which interacts with the SRF DNA bind-clear import. MAL associates with unpolymerized ac-
tin through its RPEL motifs. Constitutively cytoplasmic ing domain (Hill et al., 1994).
Recent studies identified myocardin, a heart-specificMAL derivatives interfere with MAL redistribution and
Rho-actin signaling to SRF. MAL associates with sev- SRF coactivator (Wang et al., 2001). Myocardin is closely
related to MAL/MKL1, a ubiquitously expressed geneeral SRF target promoters regulated via the Rho-actin
pathway. rearranged in t(1;22)(p13;q13) AML (Ma et al., 2001;
Mercher et al., 2001) and to MAL16, the site of a lethal
insertion mutation in the mouse (Mercher et al., 2001;Introduction
Skarnes et al., 1992). The mouse homologs were subse-
quently shown to potentiate SRF activity (MRTF-A andSerum response factor (SRF) is a MADS-box transcrip-
tion factor, which controls growth-factor-regulated im- MRTF-B; Wang et al., 2002), and a mouse MAL isoform,
BSAC, was isolated in a screen for antiapoptotic factorsmediate-early (IE) genes such as c-fos and cytoskeletal
actin, and numerous muscle-specific genes (for review, (Sasazuki et al., 2002). Here, we show that MAL is a
G-actin-associated SRF coactivator, which is redistrib-Arsenian et al., 1998). SRF forms regulatory complexes
with other transcriptional regulators through its DNA uted from the cytoplasm to the nucleus in response to
Rho-induced actin polymerization.binding domain. At the c-fos promoter, for example, its
interaction with members of the ternary complex factor
(TCF) family of Ets-domain proteins allows control of Results
transcription via MAP kinase signaling (for review, Treis-
man, 1994). Inactivation of SRF impairs IE and muscle- MAL Expression in NIH3T3 Cells
specific gene expression, causes a non-cell-autonomous The three MAL family proteins each comprise a con-
gastrulation defect, and alters cell adhesive properties served N-terminal RPEL domain followed by an ORF of
(Arsenian et al., 1998; Schratt et al., 2002, 2001; Wein- approximately 800 residues containing several con-
hold et al., 2000). served motifs (Figure 1A; Mercher et al., 2001; Wang et
SRF activity is regulated independently of its interac- al., 2001, 2002). We used the EST database and pub-
tion with TCF by a novel signaling pathway controlled lished human MAL/MKL sequences (Ma et al., 2001;
Mercher et al., 2001) to identify and isolate mouse MAL
homologs. The predominant class of MAL mRNA in*Correspondence: richard.treisman@cancer.org.uk
1These authors contributed equally to this work. NIH3T3 cells is predicted to encode a protein, MAL(met),
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Figure 1. Mouse MAL Proteins Accumulate
in the Nucleus upon Serum Stimulation
(A) Conserved sequence motifs in the mouse
MAL protein family. RPEL motifs (pfam
PF02755) are indicated by red bars, basic
boxes are in black, and other conserved ele-
ments in blue. Structures of three different
MAL N termini are shown below. Bottom, se-
quences of the three N-terminal RPEL motifs:
blue, framework residues; red, divergence
from consensus.
(B) NIH3T3 MAL initiates translation N-ter-
minal to the first N-terminal ATG codon.
Lanes 1–12, lysates from NIH3T3 cells ex-
pressing C-terminally HA-tagged MAL(fl) or
derivatives, MAL(BSAC) or MAL(met), or vec-
tor alone (200 ng each) were analyzed by im-
munoblotting with antibodies against HA
(lanes 1–5 and 11–13) or MAL (lanes 6–10).
(C) Serum induces MAL nuclear accumula-
tion. Top row, endogenous NIH3T3 MAL. Sec-
ond row, cells expressing MAL(met)-HA and
NlexA transfection marker (Posern et al.,
2002) (50 ng each) stained for MAL-HA, F ac-
tin, and marker either directly, or following
extraction with 0.5% Triton X-100 (right im-
age). Third row, cells expressing MAL(fl)-HA
or MAL(BSAC)-HA (50 ng each) were treated
as indicated and stained directly for HA. Bot-
tom row, time course of MAL(met)-HA nuclear
accumulation. MAL(met)-HA was predomi-
nantly cytoplasmic in 82  3% of serum-
starved cells, and predominantly nuclear in
83  2% of serum-stimulated cells.
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with its presumptive ATG codon N-terminal to RPEL ure 2A, lanes 2–4). This complex was not formed on a
probe containing point mutations which prevent SRFmotif 2. However, in this mRNA, the ORF remains open
binding and was supershifted by both anti-MAL andN-terminal to this ATG codon and is conserved between
anti-SRF antibodies (data not shown; see Supplementalhuman and mouse at 104 of 105 preceding codons,
Figures S3A and S3B available at http://www.cell.com/including RPEL motif 1 (see Experimental Procedures).
cgi/content/full/113/3/329/DC1). Substantially greaterWe were unable to detect a second mRNA isoform,
amounts of MAL-SRF complex were generated uponMAL(BSAC), which contains all three RPEL motifs (Sasa-
removal of the entire MAL N-terminal sequence, includ-zuki et al., 2002) in our NIH3T3 cells.
ing all the RPEL motifs, indicating that these sequencesThe intact MAL cDNA, including its 5 UTR, and the
inhibit MAL-SRF complex formation (Figure 2A, lane 5).individual MAL(met) and MAL(BSAC) ORFs were in-
All the MAL derivatives also formed complexes with theserted into appropriate expression plasmids and tran-
SRF DNA binding domain (Figure 2, lane 7; Supplementalsiently expressed in NIH3T3 cells. The C-terminally HA-
Figure S3B available at above website). MAL was detect-tagged MAL(met) reading frame produced a protein of
able, albeit weakly, in SRF immunoprecipitates from se-Mr150 kDa (Figure 1B, lane 4); in contrast, expression
rum-stimulated cells (Supplemental Figure S3C avail-of the full-length cDNA produced a polypeptide of Mr
able at above website).180 kDa, which we term MAL(fl) (Figure 1B, lane 2).
Previous studies indicate that the altered-specificityMAL(BSAC) migrated with Mr160 kDa (Figure 1B, lane
SRF derivative SRF-M2 is unable to respond to signaling3). MAL(fl) comigrated with endogenous NIH3T3 cell
through the Rho pathway when bound to its cognateMAL, detected using an antiserum directed against
binding site SRE.LM (Hill et al., 1993, 1994). MALN didMAL(met) codons 1–170 (Figure 1B, lanes 6 and 7; Sup-
not interact with the SRF-M2:SRE.LM complex, consis-plemental Figure S1A available at http://www.cell.com/
tent with a potential role in Rho signaling (Figure 2B).cgi/content/full/113/3/329/DC1). To investigate MAL(fl) ini-
Functional studies also indicate that any Rho-actin path-tiation further, we mutagenized Leu-92, the first leucine
way cofactor should compete with TCF for a commoncodon in the conserved MAL ORF: a TAG codon abol-
surface on SRF (Hill et al., 1994; Murai and Treisman,ished MAL(fl) synthesis, while an ATG codon reduced
2002). We therefore tested whether the Elk-1 B box se-
but did not abolish it (Figure 1B, lanes 11–13). Thus,
quence, which directly interacts with SRF (Hassler and
NIH3T3 MAL mRNAs mostly initiate translation at codon
Richmond, 2001; Ling et al., 1997), could compete with
Leu-92 or shortly N-terminal to it.
MAL for interaction with SRF. Wild-type B box peptide,
but not a peptide containing the mutation Y159A, which
cannot bind SRF (Ling et al., 1997), inhibited complex
MAL Relocalizes to the Nucleus formation in a dose-dependent manner (Figure 2C). The
upon Serum Stimulation MAL-SRF interaction thus has two critical properties
We used the MAL antiserum to investigate the cellular expected of the putative Rho-actin coactivator.
localization of endogenous MAL in NIH3T3 cells. In se- We examined the domains of MAL required for inter-
rum-starved cells, endogenous MAL exhibited diffuse action with SRF. Deletion of basic region B1 completely
cytoplasmic staining, but became predominantly nu- abolished MAL-SRF complex formation, while removal
clear following stimulation with serum or LPA (Figure of Q-rich region significantly reduced it; deletion of the
1C). Transiently expressed MAL(met) and MAL(fl) also SAP domain had no effect (Figure 2A, lanes 8, 9, and
exhibited diffuse cytoplasmic staining in serum-starved 11). Deletion of the LZ motif significantly reduced MAL-
cells, while MAL(BSAC) exhibited a punctate cyto- SRF complex formation, but substantially increased its
plasmic localization, suggesting that its variant N-ter- mobility (Figure 2A, lane 10). Deletion of the LZ also
minal sequences are involved in targeting within the abolished the ability of MAL to self-associate in a coim-
cytoplasm (Figure 1C). The proteins did not colocalize munoprecipitation assay (Figure 2D). These data sug-
with the F actin cytoskeleton and were completely ex- gest that MAL preferentially binds SRF as a dimer, al-
tracted from the cells by mild detergent treatment (Fig- though monomeric MAL remains competent for weak
ure 1C; Supplemental Figure S2A available at above interaction. Taken together, these data show that MAL
website). Upon serum stimulation, all three MAL iso- interacts with the SRF DNA binding domain, that it binds
forms rapidly accumulated in the nucleus; accumulation preferentially as a dimer, and that MAL and TCF proteins
was readily apparent after 10 min and virtually complete interact with SRF in a mutually exclusive manner.
by 20 min, persisting for up to three hours (Figure 1C;
data not shown). Serum stimulation did not affect MAL MAL Potentiates the Activity of the Rho Pathway
protein levels (Supplemental Figure S1C available at We used reporter gene assays to assess transcriptional
above website). Regulated nuclear accumulation of MAL activation by various MAL derivatives (Figure 3A). In
proteins in response to extracellular signals suggests serum-starved cells, reporter activity was strongly po-
that it might play a role in Rho-actin signaling to SRF. tentiated by increasing amounts of MAL(met) and was
not further stimulated by coexpression of wild-type SRF,
which alone inhibited reporter activity slightly (Figure
DNA Binding Properties of the MAL-SRF Complex 3B, left; Hill et al., 1993). Potentiation of SRF activity
We next investigated the interaction between MAL and occurred at MAL(met) expression levels at which nuclear
SRF using gel mobility-shift assays. Extracts from cells MAL was detectable even in serum-starved cells (data
expressing MAL(fl), MAL(BSAC), or MAL(met) proteins not shown). In contrast, MAL(met) expression did not
activate a reporter controlled by the mutant SRF bindinggenerated small amounts of a low mobility complex (Fig-
Cell
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Figure 2. The MAL-SRF-DNA Complex
(A) Complex formation between MAL and SRF. Gel mobility-shift assays were performed using whole-cell extracts from cells expressing
MAL(fl), MAL(BSAC), MAL(met), or MAL deletion mutants; extracts were assayed either alone (lanes 1–5) or with added recombinant SRF DNA
binding domain (SRF 133-265; lanes 6–11).
(B) MAL does not interact with altered-specificity SRF-M2 at its cognate site. Extracts from cells expressing MALN with either wild-type
SRF or SRF-M2 were analyzed using the indicated probes.
(C) MAL and Elk-1 compete for the same binding site on SRF. Complex formation between MALN and SRF(133–265) was challenged with
increasing amounts of wild-type or mutant Elk-1 B box peptides. Note specific SRF-peptide interaction, revealed by increased binding of full-
length SRF (present in the extract; asterisk) and of SRF 133–265 (lanes 7, 8, 15, and 16).
(D) MAL dimerizes through the LZ motif. Extracts from cells expressing MAL(met) derivatives were analyzed by immunoprecipitation and
immunoblotting.
(E) Proteins, peptides, and SRF binding sites. Proteins are shown with conserved domains in blue the SRF-M2 mutation in white. Sequences
of the DNA binding sites for SRF and SRF-M2 are shown below.
site SRE.LM, which cannot bind wild-type SRF (Figure to serum stimulation (Figure 3E). MAL(met)C471 expres-
sion also inhibited reporter activation by activated forms3B, right; Hill et al., 1994). Coexpression of the inactive
altered-specificity SRF derivative SRF-M2, which can of RhoA and mDia1, both of which activate Rho-actin
signaling intracellularly (Figure 3E). This observationbind SRE.LM but cannot respond to Rho-actin signaling,
did not allow efficient activation by MAL, consistent with suggests that MAL contains a C-terminal activation do-
main, as does myocardin, and that MAL derivativesthe failure of SRF-M2 to interact with MAL in vitro (Figure
3B, right). which lack this domain can bind SRF but not activate
transcription. Consistent with this idea, LexA fusion pro-To assess the role of MAL in Rho-actin signaling to
SRF more directly, we examined its effect on serum- teins containing the MAL C-terminal sequences strongly
activated a LexA reporter gene; however, serum stimula-induced transcription. At low expression levels, MAL
(met) substantially potentiated serum-induced SRF re- tion did not alter transcriptional activation by these fu-
sions (Figure 3F).porter activity, and at high expression level also strongly
stimulated reporter activity in serum-starved cells (Fig-
ure 3C). Expression of C3 transferase, which ADP-ribo- Nuclear Accumulation of MAL Requires
Rho-Actin Signalingsylates and inactivates Rho, strongly inhibited reporter
activation by MAL(met) in both serum-starved and -stim- We next tested the ability of known inhibitors of Rho-
actin signaling and other pathways to inhibit serum-ulated cells (Figure 3D). In contrast, C3 transferase ex-
pression did not affect reporter activation by MALN, induced nuclear accumulation of MAL. Serum-induced
nuclear accumulation of MAL(met), MAL(fl) and MALsuggesting that the N-terminal RPEL domain may con-
trol sensitivity to Rho-actin signaling (Figure 3D; see (BSAC) was prevented upon inactivation of Rho with
C3 transferase or toxin B (Figure 4A; data not shown).below). Expression of MAL(met)C471, which lacks C-ter-
minal sequences, did not activate the reporter in serum- Treatment of cells with latrunculin B, which sequesters
actin monomer and prevents SRF activation via the Rho-starved cells, and indeed strongly inhibited its response
MAL Mediates Rho-Actin Signaling to SRF
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Figure 3. Reporter Analysis
Transfected cells were maintained in 0.5% serum and serum-stimulated where indicated.
(A) MAL derivatives used.
(B) MAL activates wild-type but not altered-specificity SRF. NIH3T3 cells were transfected with SRE.L2.luc or SRE.LM2.luc reporter plasmids
and 0, 5, 50, 100, or 250 ng MAL(met) expression plasmid, with MLV.SRF or MLV.SRF-M2 (50 ng) as indicated.
(C) MAL potentiates the serum-induced activity of SRF. NIH3T3 cells were transfected with SRF reporter 3D.ALuc and the indicated amounts
(ng) of MAL(met) expression plasmid.
(D) Rho-dependent activation of SRF by MAL(met) requires MAL N-terminal sequences. NIH3T3 cells were transfected with the indicated
plasmids with or without C3 transferase (50 ng).
(E) MAL(met)C471 inhibits signaling to SRF. NIH3T3 cells were transfected with 3D.ALuc and increasing amounts (0.1, 0.5 and 1.0 g) of
MAL(met)C471 expression plasmid, and stimulated with 15% FCS or by coexpression of activated RhoA.V14 or activated mDia1 (F1F2;
Copeland and Treisman, 2002) (100 ng each) as indicated.
(F) The MAL C terminus activates transcription. NIH3T3 cells were transfected with LexOP2.luc reporter and 5, 50, and 250 ng expression
plasmid encoding the indicated LexA derivatives.
actin pathway (Sotiropoulos et al., 1999) completely serum-induced MAL(met) translocation was observed
upon inhibition of MEK-ERK signaling by U0126, of Giblocked serum-induced nuclear accumulation of tran-
siently expressed MAL(met) (Figure 4A). No inhibition of and ERK signaling by pertussis toxin, of the Rho effector
Cell
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Figure 4. Nuclear Translocation of MAL Involves RhoA-Actin Signaling
Transfected NIH3T3 cells were processed for immunofluorescence as indicated after serum stimulation (A and B) or serum starvation (C).
(A) Transiently expressed MAL(met) requires Rho-actin signaling for nuclear accumulation. Cells expressed flag- or HA-MAL(met) (50 ng) with
C3 transferase (50 ng), interfering myc-Dia1 (F1F21; Copeland and Treisman, 2002) (200 ng) or flag-VASP (B; Grosse et al., 2003) (200 ng),
or different flag-actins (wild-type, 1 g; R62D, 200 ng). Where indicated cells were pretreated with latrunculin B and additionally stained for
DNA (DAPI) and F actin (phalloidin). Figures give proportion of cells with predominantly cytoplasmic MAL.
(B) Nuclear accumulation of endogenous MAL requires Rho-actin signaling. Cells expressed interfering myc-Dia1, flag-VASP, or actin derivatives
as in (A). Arrows indicate transfected cells.
(C) Activation of RhoA-Actin signaling induces nuclear accumulation of MAL(met). Cells expressing HA- or flag-tagged MAL(met) (50 ng) with
indicated activators (50 ng), actins (200 ng) or vector. Where indicated, cells were treated with cytochalasin D, and additionally stained for
DNA and F actin. Figures give proportion of cells with predominantly nuclear MAL.
MAL Mediates Rho-Actin Signaling to SRF
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kinase ROCK by Y27632, or of PI-3 kinase signaling by fected NIH3T3 cells. Data are summarized in Figure 5A.
MAL(fl) and MAL(BSAC) exhibited regulated transloca-LY294002 (data not shown).
tion upon serum stimulation, as did MAL(met) (FigureWe previously demonstrated that inactive deletion de-
5A), indicating that sequences N-terminal to the MALrivatives of mDia1 (F1F21) and VASP (VASPB) can
(met) ATG, including RPEL motif 1, are not absolutelyspecifically interfere with operation of the Rho-depen-
required for regulation. In contrast, MALN, which lacksdent signaling pathway to SRF (Copeland and Treisman,
all the RPEL motifs, was constitutively nuclear-localized2002; Grosse et al., 2003). Expression of these mutants
in serum-starved cells (Figures 5A and 5B). We testedeffectively blocked serum-induced nuclear accumula-
the functional significance of RPEL motifs 2 and 3 bytion of both transiently expressed MAL(met) (Figure 4A)
introducing point mutations into their conserved core.and endogenous MAL (Figure 4B). Overexpression of
MAL(met) derivatives containing point mutations in botheither wild-type  actin or its nonpolymerizable mutant
RPEL motifs (RR33/77DD or PP34/78AA) were also nu-derivatives  actin G13R and R62D is also sufficient to
clear in serum-starved cells (Figures 5A and 5B). Re-inhibit Rho-actin signaling to SRF (Posern et al., 2002;
moval of greater extents of N-terminal sequence gener-Sotiropoulos et al., 1999). Actin overexpression inhibited
ated proteins, which were distributed diffusely throughoutserum-induced nuclear accumulation of transiently ex-
the cell regardless of stimulation (Figures 5A and 5B).pressed MAL(met) or endogenous MAL (Figures 4A and
We used C3 transferase coexpression to test whether4B, lower images). Taken together, these results show
nuclear accumulation of MALN and the RPEL mutantsthat operation of the Rho-actin pathway is required for
required functional Rho. In the presence of C3, bothMAL nuclear translocation in response to serum.
MALN and the MAL(met) RPEL mutants remained nu-
clear (Figure 5B), and their ability to activate transcrip-
Alterations in Actin Dynamics Induce MAL tion was unaffected (Figure 3D; data not shown). These
Nuclear Accumulation data establish that the integrity of the N-terminal do-
Many proteins involved in Rho GTPase signaling to actin main, particularly RPEL motifs 2 and 3, is required for
dynamics can promote actin polymerization and SRF linkage of MAL nuclear accumulation to the Rho-actin
activation upon overexpression either as wild-type or signal pathway. The function of the RPEL motifs will be
activated forms. These include RhoA, Cdc42, and Rac analyzed further below.
(Hill et al., 1995); LIM kinase (Geneste et al., 2002; Sotiro- We also examined the effect of deleting other con-
poulos et al., 1999); profilin (Sotiropoulos et al., 1999); served elements of MAL. Deletion of MAL(fl) sequences
mDia1 and mDia2 (Copeland and Treisman, 2002; Soti- C-terminal to residue 471 resulted in predominantly nu-
ropoulos et al., 1999; Tominaga et al., 2000); VASP clear localization of the protein even in serum-starved
(Grosse et al., submitted; Sotiropoulos et al., 1999); and cells, as did truncation of MAL(met) to residue 471 or 256
WASP and N-WASP (Geneste et al., 2002; Sotiropoulos (Figure 5A). Appropriate regulation could be restored
et al., 1999). We therefore tested the effect of expressing to the MAL(met)C471 truncations by addition of MAL
active forms of these proteins on MAL subcellular local- C-terminal sequences (Figure 5A). In contrast to the
ization. In each case, expression was sufficient to induce MALN and the RPEL mutants, however, both
nuclear translocation of MAL(met) in serum-starved cells MAL(fl)C471 and MAL(met)C471 required functional Rho
(Figure 4C; data not shown). for nuclear accumulation, remaining cytoplasmic upon
SRF can also be activated in the absence of extracel- inactivation of Rho by C3 transferase (Figure 5B). A
lular signals by certain actin binding drugs, which inter- deletion derivative of MAL(met) lacking the Q-rich do-
fere directly with the actin treadmilling cycle (Sotiro- main (MAL(met)Q) behaved in a similar manner (Figure
5B). Deletion of the SAP or LZ motifs had no effectpoulos et al., 1999). Cytochalasin D and swinholide A,
on regulation (Figure 5A). These results show that thewhich do not promote actin polymerization but never-
C-terminal and Q box sequences are not required fortheless activate SRF, induced nuclear accumulation of
the response to signal per se, suggesting that they maytransiently expressed MAL (Figure 4C; data not shown).
mediate cytoplasmic retention or nuclear export.Jasplakinolide, which stabilizes F actin and activates
To investigate sequences required for nuclear importSRF (Sotiropoulos et al., 1999), also efficiently induced
in response to signal, we focused on two regions richMAL nuclear accumulation (data not shown). Expression
in basic residues: B1, a basic region homologous to oneof  actin mutants S14C and V159N, which apparently
first identified in myocardin (Wang et al., 2001), and B2,stabilize F actin and strongly activate SRF (Posern et
a related sequence between RPEL motifs 2 and 3 (seeal., 2002) also induced efficient MAL(met) nuclear accu-
Figure 1A). Removal of the MAL(met) B1 region, whichmulation, as did expression of a third mutant of this
abolishes complex formation with SRF, reduced the effi-type, actin G15S (F.M. and G.P. unpublished data; Figure
ciency of serum-induced nuclear accumulation such4C). These data establish an intimate correlation be-
that many cells exhibited only partial MAL accumulationtween activation or inhibition of Rho-actin signaling and
in the nucleus (Figure 5A). This suggests that B1 is in-accumulation of MAL in the nucleus or cytoplasm, re-
volved in nuclear import, and consistent with this view,spectively.
removal of B1 from the constitutively nuclear mutant
MALN resulted in its relocation to the cytoplasm (Fig-
MAL Nuclear Accumulation Involves MAL ure 5A). While removal of B2 alone had no effect on
N- and C-Terminal Sequences MAL(met) regulation, removal of both B1 and B2 pre-
To define sequences required for regulated nuclear ac- vented its serum-induced nuclear accumulation (Figure
cumulation of MAL, we analyzed relocalization of mutant 5A; see below).
The results presented in this section thus show that:MAL derivatives following serum stimulation of trans-
Cell
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Figure 5. MAL N- and C-Terminal Sequences Have Regulatory Functions
(A) MAL domains required for serum-induced MAL redistribution. Cells expressing MAL derivatives (50 ng) were serum-starved or -stimulated
as indicated before staining for the MAL epitope tag. N and C, predominantly nuclear or cytoplasmic localization in 80% of the cells,
respectively; N/C, localized throughout the cell.
(B) Dependence on Rho distinguishes two types of nuclear MAL mutant. Cells expressed MAL derivatives (50 ng) with or without C3 transferase
(50 ng). Merged images for MAL and F actin are shown. Proportions of cells exhibiting predominantly nuclear MAL localization are shown.
(C) Serum-induced MAL(met) phosphorylation. Cells expressing MAL(met) or derivatives (200 ng) were left unstimulated or serum-stimulated
for 1 hr and analyzed by immunoblotting. Top, extracts were analyzed directly or following immunoprecipitation and treatment with  phospha-
tase. Center, MAL in cells treated with U0126 (10 M) or bisindolylmaleimide (BIM; 10 M) or with coexpressed C3. Bottom, cells expressing
different MAL truncations. NS, non-specific product.
(1) signal serum-regulated nuclear accumulation of ERK signaling therefore contribute to phosphorylation
of MAL.MAL(met) requires RPEL motifs 2 and 3; (2) the MAL Q
box and C-terminal sequences are required for nuclear We used different truncation derivatives of MAL to
gain insight into the location of the phosphorylations.export or cytoplasmic retention; and (3) the basic motifs
B1 and B2 are required for nuclear accumulation in re- MAL(met) lacking sequences C-terminal to position 471
exhibited a minimal change in Mr following serum stimu-sponse to Rho-actin signaling.
lation (Figure 5C, bottom). In contrast MALN473, which
comprises residues 437–929 alone, was phosphorylatedMAL C-Terminal Sequences Are Subject
upon serum stimulation, as was MAL(met)C631, whichto Serum-Induced Phosphorylation
lacks sequences C-terminal to residue 631 (Figure 5C,Serum stimulation results in the activation of multiple
bottom). These data indicate that the C-terminal se-kinase-mediated signal pathways downstream of both
quences of the protein are likely targets for phosphoryla-Rho and Ras. We therefore tested whether MAL nuclear
tion. We note, however, that the C-terminally truncatedaccumulation correlated with its phosphorylation. On
MAL mutant MAL(met)C471 remains dependent on sig-SDS-PAGE, endogenous MAL and transfected MAL
naling for nuclear import. Phosphorylation is thus not a(met) exhibited an apparent increase in Mr upon serum
prerequisite for the control of MAL nuclear accumulationstimulation (Figure 5C, top; Supplemental Figure S1C
by its N-terminal domain via Rho-actin signaling.available at http://www.cell.com/cgi/content/full/113/3/
329/DC1). This reduction in mobility was sensitive to
treatment with  phosphatase, indicating that it results MAL Associates with Actin via the RPEL Motifs
The results presented above show that inhibition of Rho-from phosphorylation; this may occur at serine or threo-
nine residues, since MAL did not react with anti-phos- actin signaling or overexpression of actin itself can in-
hibit nuclear translocation of MAL through a mechanismphotyrosine antibodies (Figure 5C, top). To assess the
relevance of Rho and Ras signaling for MAL phosphory- dependent on the integrity of the N-terminal RPEL mo-
tifs. We therefore investigated whether this reflects thelation, we used C3 transferase coexpression and U0126
treatment to inactivate Rho-actin and MEK-ERK signal- association of MAL with actin in vivo. First, mutant actins
designed to localize to novel cellular locations were con-ing, respectively. Inactivation of Rho substantially re-
duced but did not prevent the serum-induced increase structed and their ability to alter the localization of co-
expressed MAL(met) tested by immunofluorescencein MAL Mr, while U0126 had a lesser effect; treatment
of C3-expressing cells with U0126, however, abolished assay. Wild-type actin or nonpolymerizable actin R62D
tagged with the SV40 NLS efficiently accumulated in theit (Figure 5C, center). A PKC inhibitor, bisindolylmalei-
mide, had no effect (Figure 5C, center). Both Rho and nucleus, and in the presence of these actins coex-
MAL Mediates Rho-Actin Signaling to SRF
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Figure 6. Actin Interacts with the MAL RPEL Domain
(A) MAL colocalizes with actin. Serum-starved transfected cells expressed the indicated actins (500 ng) together with HA-tagged MAL(met)
(100 ng). In this experiment, 48% of cells expressing GAP-R62D exhibited perinuclear localization of both actin and MAL(met). NLS-actin was
nuclear in 78% of transfected cells, and of these 96% also displayed nuclear MAL(met). Wild-type actin did not affect MAL(met) localization
in unstimulated cells (data not shown).
(B–E) MAL coimmunoprecipitates with actin. Serum-starved cells expressing flag-tagged actin with or without HA-tagged MAL(met) (1 g
each) were stimulated with serum or actin binding drugs as indicated. Extracts were analyzed directly (lysate panels) or following immunoprecipi-
tation with anti-flag antibody (IP panels). LB, latrunculin B; CD, cytochalasin D; SwA, swinholide A.
(B) Actin association requires the N-terminal RPEL motifs.
(C) Endogenous MAL coimmunoprecipitates with actin.
(D) Serum stimulation reduces association of actin with endogenous MAL. Cells were serum-stimulated for the indicated times. A subinhibitory
level of actin (500 ng) was expressed for this experiment.
(E) Actin binding drugs which activate SRF disrupt actin-MAL association.
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pressed MAL(met) was also nuclear, even in the absence MALNB1, MAL(met)B1B2, and MAL(met)B1 (see
Figure 5A). We reasoned that these mutants might se-of signal (Figure 6A, top; data not shown). Similarly,
actin R62D tagged with a GAP43 membrane targeting quester endogenous MAL proteins in the cytoplasm,
since they retain the LZ sequence required for MALsequence (McCabe and Berthiaume, 1999) exhibited
strong perinuclear staining in about half the transfected dimerization (see Figures 2A and 2D).
We used immunofluorescence assays to test whethercells, presumably at the Golgi, as did coexpressed MAL
(met) (Figure 6A, bottom). These results suggest that cytoplasmic MAL mutants can prevent nuclear accumu-
lation of intact MAL. Derivatives of the proteins lackingactin physically associates with MAL in vivo, and that
this is not dependent on actin’s ability to polymerize. the LZ sequence served as controls. The basic box mu-
tants MAL(met)B1B2 and MAL(met)B1 strongly inhib-Actin-MAL interactions were investigated more di-
rectly using a coimmunoprecipitation assay. Extracts ited nuclear accumulation of coexpressed MAL(met)
upon serum stimulation, provided that they containedfrom cells expressing HA-tagged MAL(met) with or with-
out different flag-actins were immunoprecipitated with the LZ (Figure 7A, top; data not shown). Both mutants
substantially reduced serum-stimulated activity of a co-flag antibodies and tested for the presence of HA-
tagged MAL proteins. In these experiments, flag-actin transfected SRF reporter in a dose-dependent manner,
and this required the LZ (Figure 7B). Expression of MALis expressed at around the same level as endogenous
actin, as assessed by quantitative DNAse I and phalloi- (met)B1B2 also strongly inhibited serum induction of
a chromosomal SRF reporter gene, but did not preventdin staining for cellular G- and F actin, respectively (Pos-
ern et al., 2002). MAL(met), MAL(fl), and MAL(BSAC) activation of the cellular c-fos and egr-1 genes, which
are regulated independently of Rho-actin signaling (Fig-were all readily detectable in immunoprecipitates of
wild-type flag-actin (Figure 6B, lanes 1 and 2; data not ure 7C; Sotiropoulos et al., 1999). Expression of MAL
(met)B1B2 and MAL(met)B1 did not affect serum-shown), as was endogenous NIH3T3 MAL (Figure 6C).
MAL did not coimmunoprecipitate with flag-hSmad4 or induced activity of an Elk-1 reporter gene system (data
not shown). The MAL(met)B1B2 and MAL(met)B1 mu-with anti-myc beads (data not shown). Interaction of
MAL(met) with actin did not require sequences C-ter- tants thus represent specific inhibitors of Rho-actin sig-
naling, which act at the level of MAL rather than SRF.minal to residue 471, but was absolutely dependent on
the N-terminal domain, in particular the integrity of RPEL These data establish that functional MAL is required for
SRF activation by extracellular signals.motifs 2 and 3 (Figure 6B, compare lanes 2, 5, 8, and
11). Association was not affected by the deletion of basic
motif B2, which lies between RPEL2 and RPEL3 (data MAL Associates with SRF Targets Regulated
not shown). The nonpolymerizable actin mutant R62D by Rho-Actin Signaling
interacted with MAL(met) in a similar way to wild-type Finally, we used chromatin immunoprecipitation (ChIP)
actin (Figure 6B), consistent with the notion that it is assays to test whether MAL associates specifically with
unpolymerized actin which controls MAL activity (Pos- genes activated by Rho-actin signaling. We used the
ern et al., 2002; Sotiropoulos et al., 1999). actin binding drug swinholide to specifically activate
We used the coimmunoprecipitation assay to test actin-responsive SRF target genes, which include vin-
whether activation of Rho-actin signaling alters actin- culin, SRF, and cyr61, but not c-fos and egr-1 (K. Murai
MAL association. Serum stimulation caused a transient and R.T., unpublished data; Gineitis and Treisman, 2001;
decrease in the amount of endogenous MAL coimmuno- Sotiropoulos et al., 1999). SRF was specifically associ-
precipitated with flag-actin, reaching a minimum at 10 ated in the ChIP assay with all the above-mentioned
min following stimulation and recovering slowly thereaf- promoters in both untreated and swinholide-treated
ter (Figure 6D, lanes 2–7). Latrunculin B treatment, which cells (Figure 7D, lanes 3 and 4). Following swinholide
inhibits SRF activation, effectively blocked serum- treatment, MAL became associated with the promoters
induced dissociation of the actin-MAL complex (Figure of the SRF, vinculin and cyr61 genes but not those of
6D, lane 8). Similar results were obtained with cotrans- c-fos or egr-1 (Figure 7D, lanes 7 and 8). In contrast
fected MAL(met) (data not shown). Unlike latrunculin B, SAP-1, a member of the TCF family of SRF cofactors,
cytochalasin D and swinholide strongly activate SRF was associated only with the egr-1 promoter in both
(Sotiropoulos et al., 1999), and treatment of cells with untreated and swinholide-treated cells. The SRF cofac-
these drugs also substantially reduced actin association tors MAL and SAP-1 therefore associate differentially
with both contransfected MAL(met) (Figure 6E) and en- with SRF target genes.
dogenous MAL (data not shown). This observation is
consistent with our previous proposal that cytochalasin Discussion
D and swinholide, but not latrunculin B, disrupt the regu-
latory function of G actin (Sotiropoulos et al., 1999). In this paper, we have identified the MAL protein as a
Together, these results show that actin associates with signal-regulated SRF coactivator. MAL activity is con-
MAL via the RPEL motifs and that Rho-actin signaling trolled by a mechanism in which activation of actin poly-
leads to dissociation of this complex. merization by Rho induces its redistribution from the
cytoplasm to the nucleus. The effect of activated or
inhibitory derivatives of components of the Rho-con-Functional MAL Is Required for SRF Activation
To establish the relevance of MAL function for SRF acti- trolled actin polymerization pathway on the subcellular
distribution of MAL correlates completely with their ef-vation, we first studied dominant interfering mutants of
MAL. Three basic box mutants which remain cyto- fect on SRF activity. Both wild-type cytoskeletal actin
and nonpolymerizable actin mutants associate withplasmic upon serum stimulation were described above:
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MAL N-terminal RPEL motifs, which are also required
for the response to Rho signaling. Nuclear MAL is re-
quired for SRF activation via the Rho-actin pathway,
and chromatin immunoprecipitation shows that MAL as-
sociates specifically with SRF target genes regulated
via the pathway. MAL regulation thus provides a direct
link between actin cytoskeletal dynamics in the cyto-
plasm and transcriptional activation in the nucleus. It is
likely that aberrant regulation of a subset of SRF target
genes forms the basis for transformation in t(1;22)
(p13;q13) AML, in which MAL is fused to the RBM/OTT
gene (Ma et al., 2001; Mercher et al., 2001). The func-
tional elements of MAL and the structure of the Rho-
actin-MAL signal pathway are summarized in Figure 8.
Translation of the predominant MAL RNA present in
NIH3T3 cells is initiated upstream of the first ATG codon
in the open reading frame, most likely at a leucine codon
at position 92. The resulting protein, MAL(fl), which con-
tains all three RPEL motifs, has an Mr similar to that of
endogenous NIH3T3 cell MAL. A second MAL isoform,
MAL(BSAC), in which the RPEL motifs are preceded by
distinct N-terminal sequences, was not detectable in
our cells. Both proteins are cytoplasmic in serum-
starved cells but accumulate in the nucleus upon serum
stimulation. MAL(BSAC) is localized in a punctate pat-
tern rather than diffusely, however, suggesting a tar-
geting role for its N-terminal sequences. Heightened
activity of the Rho pathway may account for the nuclear
localization of BSAC in 293 cells (Sasazuki et al., 2002).
MAL does not colocalize with F actin.
Mutational analysis of MAL revealed a complex set
of regulatory sequences (Figure 8A). Two classes of MAL
mutant are nuclear in serum-starved cells, but can be
distinguished according to whether nuclear accumula-
tion requires functional Rho. MAL mutants which lack
the N-terminal RPEL domain, or which contain point
mutations in RPEL motifs 2 and 3, do not require basal
Rho activity for nuclear accumulation, indicating that
the RPEL motifs are required for Rho-regulated nuclear
accumulation. In contrast, MAL mutants which lack the
Q-box or C-terminal sequences still require functional
Rho for their accumulation in the nucleus. This indicates
that these sequences are not required for the response
to Rho signaling per se. Instead, they may mediate either
export of MAL from the nucleus or its retention in the
cytoplasm. Two basic motifs, B1 and B2, are required
for effective nuclear accumulation of MAL in response to
Rho-actin signaling (Figure 8A). Preliminary experiments
indicate that the basic motifs do not appear to functionFigure 7. MAL Regulates SRF Target Promoters In Vivo
as autonomous NLS elements, since they do not pro-(A) Cytoplasmic MAL(met) deletion mutants retain wild-type MAL
mote nuclear localization when linked to pyruvate ki-(met) in the cytoplasm. Cells expressing cytoplasmic flag-MAL(met)
nase, a cytoplasmic protein (F.M., unpublished data).derivatives B1B2 or B1B2LZ (250 ng) with intact HA-tagged
MAL(met) (50 ng) were serum-stimulated before staining as indi- Mutants lacking the basic motifs remain cytoplasmic
cated. Proportion of cells with predominantly cytoplasmic MAL(met) upon serum stimulation and retain wild-type MAL in the
is indicated. cytoplasm: they thus act as Rho-actin pathway-specific
(B) Cytoplasmically restricted MAL derivatives inhibit SRF activation.
SRF inhibitors.SRF reporter 3D.ALuc activity was assessed in cells expressing
Our studies show that MAL associates with actin inMAL derivatives as indicated.
vivo. Although the data are consistent with the view that(C) Interfering MAL mutants specifically inhibit Rho-actin signaling to
SRF. Serum-starved or -stimulated 3AD.AfosHA reporter or NIH3T3 MAL directly binds actin, we have as yet been unable to
cells expressing MALB1B2 (250 ng) and stained for inhibitory MAL
proteins, SRF reporter product, Egr-1, or Fos. Marker-positive cells
in untransfected/MALB1B2-expressing cells are indicated.
30 min. Chromatin immunoprecipitates were prepared and analyzed(D) MAL associates with SRF targets regulated by Rho-actin signal-
by PCR as indicated.ing. Serum-starved cells were treated with 1 M swinholide A for
Cell
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Figure 8. MAL and Its Relationship to Rho
Signaling and Actin Dynamics
(A) Functional elements of the MAL protein.
Functional elements are shown.
(B) The Rho-actin signal pathway and models
for MAL nuclear accumulation. Top, control
of actin treadmilling at the levels of F actin
assembly and severing/disassembly via the
Rho effectors ROCK-LIMK and mDia. Titra-
tion model for regulated MAL nuclear accu-
mulation is shown bottom left. Note that the
data do not exclude the operation of an addi-
tional active import mechanism, shown at the
right. Red circle represents either MAL nu-
clear import signal occluded by actin associ-
ation or export signal activated by actin asso-
ciation. For discussion see text.
detect direct interaction between the purified proteins, regulated in response to the level of either G actin itself
or a G actin subpopulation defined by interaction withsuggesting that additional cofactor(s) may be involved.
The RPEL motifs are critical for actin-MAL association, actin binding proteins or nucleotide-loading status. In
the simplest model, G actin, perhaps acting with a cofac-which is abolished by point mutations at the conserved
core of motifs 2 and 3. Intriguingly, in myocardin RPEL tor, would titrate MAL and thereby occlude nuclear im-
port signals or create a nuclear export signal; in eithermotif 2 mismatches the consensus (RS—SL), sug-
gesting that it might exhibit a reduced affinity for actin. case, depletion of the G actin pool by Rho-induced actin
polymerization would result in MAL nuclear accumula-Indeed, transiently expressed myocardin is nuclear, re-
gardless of Rho signaling, and this is due to its N-ter- tion (Figure 8B, left). MAL nuclear accumulation can
also be induced by actin binding drugs, which directlyminal RPEL region (F.M., unpublished data). In contrast,
the third MAL family protein, MAL16/MRTF-B (Mercher interfere with actin-MAL association, consistent with our
previous proposal (Sotiropoulos et al., 1999). We cannotet al., 2001; Wang et al., 2002), contains RPEL motifs
similar to those of MAL, suggesting that it may be simi- exclude the possibility that an additional positively act-
ing G actin subpopulation exists which binds MAL inlarly regulated. In all three MAL family members and the
single Drosophila MAL ortholog (GenBank NM167965), such a way as to promote its nuclear accumulation (Fig-
ure 8B, right). Our data do not address the mechanismhowever, RPEL motif 1 has the variant core sequence
RR—EL (Figure 1A), but the functional significance of of MAL downregulation: it is likely that additional regula-
tory mechanisms must operate, since MAL remains nu-this is unclear. One other family of RPEL proteins exists,
each with a single N-terminal “variant” motif and a clear even after the shutdown of target gene expression
(see Gineitis and Treisman, 2001).C-terminal cluster of three motifs (e.g., GenBank
BC012871). It will be interesting to test whether these Serum stimulation also induces MAL C-terminal phos-
phorylation via both Rho- and MEK-ERK dependent sig-proteins also associate with G actin.
Considered together, our data suggest a simple nal pathways. The finding that nuclear accumulation of
MAL mutants lacking the C-terminal sequences is stillscheme for regulation of MAL subcellular localization
by Rho-actin signaling (Figure 8B). MAL localization is dependent on Rho signaling, however, suggests that
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Bank BB642124 represent MAL RNAs containing an ORF with firstphosphorylation is not a prerequisite for serum-induced
in-frame ATG at RPEL motif 2, followed by 929 codons (MAL(met),MAL nuclear accumulation and SRF activation. Consis-
Figure 1A; recently published as MRTF-A, AF532597; Wang et al.,tent with this idea, we have observed that expression
2002). This ORF is conserved between human and mouse ESTs at
of activating actin mutants (Posern et al., 2002) can 104 out of the 105 potential codons N-terminal to the first ATG,
induce nuclear accumulation of MAL without its con- including RPEL motif 1. (2) ESTs such as BB842845 also contain
the MAL(met) open reading frame, preceded by RPEL motif 1, andcomitant phosphorylation (F.M. and G.P. unpublished
11 distinct N-terminal codons bounded by an in-frame stop codon.data). Nevertheless, we cannot exclude the possibility
(3) ESTs such as GenBank BB850403 represent a MAL mRNA iso-that regulated phosphorylation of MAL may control its
form encoding the BSAC protein, which contains RPEL motifs 1–3nuclear accumulation under circumstances in which sig-
preceded by a third distinct 14 residue N-terminal sequence follow-
naling does not regulate actin dynamics. It also remains ing an in-frame ATG codon (see XM128296; Sasazuki et al., 2002).
possible that phosphorylation regulates nuclear export, MAL mutants are as follows, numbering for MAL(met):N,1-80;B1,
223-248; B2, 57-65; Q, 264-285; SAP, 349-386; LZ, 520-560;cytoplasmic retention, or even transcriptional activation.
other mutants are described in the Figures.The MAL N-terminal sequences act to inhibit MAL-
SRF complex formation. We are currently testing
Expression and Reporter Plasmidswhether this reflects association of MAL with actin pres-
Full details are available on request. MAL(met) cDNA was isolatedent in the extracts used for the assays. Inhibition of
by PCR from an NIH3T3 cDNA library (Clontech) using EST-derived
MAL-SRF complex formation by actin would set a oligonucleotides. The MAL(met) mRNA 5UTR was isolated from
threshold level of signal for SRF activation and would NIH3T3 cells by RACE-PCR; oligonucleotides were used to create
explain the inhibition of SRF activity by expression of the MAL(BSAC) N terminus. MAL derivatives were expressed with
N- or C-terminal flag or HA-tags in EFplink (Sotiropoulos et al.,NLS-actin (Posern et al., 2002). The properties of the
1999), or for intact MAL(fl), pcDNA3. Expression plasmids for SRFMAL-SRF interaction are consistent with our previous
derivatives, Rho proteins and effectors, actins, VASP, and C3 trans-studies of Rho-actin signaling to SRF. MAL does not
ferase were as described (Copeland and Treisman, 2002; Grosse et
form complexes with the altered-specificity SRF deriva- al., 2003; Hill et al., 1993, 1994; Posern et al., 2002; Sotiropoulos
tive SRF-M2, which cannot mediate serum-induced et al., 1999). GAP43-actin contains an N-terminal MLCCMRRTKQV
transcription activation (Hill et al., 1993, 1994). The pep- peptide (McCabe and Berthiaume, 1999). Reporter plasmids were
3DA.Luc and MLV-lacZ (Geneste et al., 2002); SRE.L2.luc, SRE.tide competition experiments indicate that the SRF sur-
LM2.luc, and 2LexOP.luc are derivatives of CAT reporters (Sotiro-faces contacted by MAL overlap with those contacted
poulos et al., 1999).by TCF, consistent with our previous observations that
TCF binding inhibits Rho-actin signaling to SRF (Hill et
Cell Lines and Transfections
al., 1994; Murai and Treisman, 2002). In MAL, basic re- NIH3T3 or SRE.FosHA cells in 6-well dishes were transfected using
gion B1 is essential for interaction with SRF, while in lipofectamine (Invitrogen). DNA inputs (total 1 g) were 40 ng 3DA.
contrast to myocardin (Wang et al., 2001) the Q box is Luc (50ng for SRE.L2.luc, SRE.LM2.luc or 2xLexOPluc), 150 ng MLV-
LacZ reference, with expression plasmids as in figure legends. Afternot absolutely required. The lesser contribution of the
maintenance in 0.5% FCS for 18 hr, serum stimulation was for 7 hr.MAL Q box to SRF interaction may reflect the dimeric
Normalized data were expressed relative to reporter activation bynature of MAL compared with myocardin, which appears
the constitutively active SRF derivative SRF-VP16 (50 ng), performed
to bind SRF as a monomer (A-I.Z., unpublished data). in parallel in every set of transfections, and presented as mean 
The chromatin immunoprecipitation experiments, SEM of 3 independent experiments (Copeland and Treisman, 2002).
DNA binding studies, and analysis of interfering MAL For immunofluorescence, transfected cells were kept in DME/1
mg/ml BSA before serum stimulation or drug treatments (Sotiro-mutants indicate that MAL and the SAP-1 TCF associate
poulos et al., 1999) for one hour (or as indicated) before processing.with distinct subsets of SRF target genes, consistent
with previous studies of signaling to SRF target genes
Antibodies and Immunofluorescence(Gineitis and Treisman, 2001; Murai and Treisman, 2002;
Immunofluorescence and imaging was as described (SotiropoulosSotiropoulos et al., 1999). At least some muscle-specific
et al., 1999; Posern et al., 2002). Primary antibodies were rabbit anti-
genes are responsive to Rho-actin signaling (Mack et flag (Sigma), mouse anti-flag M2 (Sigma), mouse anti-HA 12CA5
al., 2001), and it will be interesting to elucidate the role (Cancer Research UK and Roche), and mouse anti-myc 9E10 (Can-
cer Research UK), used at 1/100 to 1/300 dilution. MAL antiseraof MAL at those promoters. Several SRF target genes
were produced in rabbits immunized with GST-MAL(met) residuesdependent on Rho-actin signaling are involved in either
1–170, affinity-purified on protein A, and depleted of anti-GST activ-cytoskeletal maintenance or cell adhesion (Gineitis and
ity, and used at 1/100 dilution. Secondary antibodies were FITC-Treisman, 2001; Sotiropoulos et al., 1999); moreover,
and TRITC-anti-mouse and anti-rabbit (DAKO and Jackson Labora-
deletion of the mouse SRF gene disrupts cytoskeletal tories) used as directed. TRITC-labeled phalloidin (Molecular
functions and prevents gastrulation (Arsenian et al., Probes) was used at 33–66 nM. For quantitation, MAL localization
was scored as predominantly nuclear, predominantly cytoplasmic,1998; Schratt et al., 2002, 2001; Weinhold et al., 2000).
or evenly distributed in 80–120 cells.There is increasing evidence that both Rho signaling
and SRF target gene expression are involved in the epi-
Immunoblotting, Immunoprecipitations, and ChIPthelial-mesenchymal transition thought important for tu-
Immunoblotting was by standard techniques. For immunoprecipita-mor progression (Bhowmick et al., 2001; Oft et al., 2002;
tions, 2 g DNA was transfected per 9 cm plate. For actin experi-
Psichari et al., 2002). We speculate that MAL signaling ments, cell lysates in RIPA were immunoprecipitated in 1% TX (Pos-
controls a specific set of SRF target genes involved in ern et al., 2000), using M2 anti-flag or anti-HA agarose beads
cell morphology, adhesion, and movement. (Sigma). Actin binding drugs were present throughout processing
where appropriate. For dephosphorylation, immunoprecipitates
were incubated in  phosphatase buffer with or without enzymeExperimental Procedures
(NEB) for 3 hr at 30	C. For MAL dimerization assays, extracts were
immunoprecipitated with M2 anti-flag or control anti-myc agaroseMAL cDNA Sequences and Mutants
Examination of the mouse and human EST databases reveals three beads. ChIP assays were as described (Alberts et al., 1998) using
anti-SRF and anti-SAP1a antibodies (4 g/ml Santa Cruz, sc-335different classes of MAL cDNA (Figure 1A). (1) ESTs such as Gen-
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and sc-13030, respectively) at 20	C for 1 hr. Primer details are avail- Bouman, D., Li, Y., Mehta, P.K., Nizetic, D., et al. (2001). Fusion of
two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acuteable on request.
megakaryoblastic leukemia. Nat. Genet. 28, 220–221.
Gel Mobility Shift Assays Mack, C.P., Somlyo, A.V., Hautmann, M., Somlyo, A.P., and Owens,
Gel shift assays used DNA binding probes from c-fos promoter G.K. (2001). Smooth muscle differentiation marker gene expression
mutants TCF (SRE.L) and TCFSRF (SRE.LM), with purified is regulated by RhoA-mediated actin polymerization. J. Biol. Chem.
SRF(133–265) and MAL derivatives produced by transient transfec- 276, 341–347.
tion (Murai and Treisman, 2002). Peptide competition assays con- McCabe, J.B., and Berthiaume, L.G. (1999). Functional roles for fatty
tained 0, 0.8, 4, or 20 M of Elk-1 B-box peptides (Figure 2C; Ling acylated amino-terminal domains in subcellular localization. Mol.
et al., 1997). Biol. Cell 10, 3771–3786.
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